Latest news with #Nucleic
Time of India
14-05-2025
- Science
- Time of India
IISER-Bhopal team develops web-based solution to predict bacterial enzymes for pollutant breakdown
Bhopal: The widespread industrial growth and urbanisation have led to greater use of synthetic chemicals, including pesticides, fertilisers, and various plastics (PE, PET, PU, PVC). Poor waste management practices resulted in these chemicals and heavy metals building up in soil and water bioremediation methods require extensive laboratory work and costly analytical techniques. While natural microbial enzymes can break down complex pollutants, their identification using current methods is time-consuming and requires significant resources. A team in Bhopal plans to simplify and streamline the bioremediation process. XenoBug , a web-based solution developed by a team at IISER Bhopal , uses machine learning, neural networks, and chemo-informatics to predict bacterial metabolic enzymes capable of biodegrading specific contaminants. The system houses a comprehensive database containing approximately 3.3 million enzyme sequences from environmental metagenomes and 16 million enzymes from 38,000 bacterial genomes. The study was recently published in Nucleic Acids Research Genomics and Bioinformatics (2025). A team led by Dr Vineet Sharma, professor department of biological sciences in IISER has done the research work and the team also includes Dr Aditya S Malwe and Usha Longwani. The platform uses 6,814 enzyme substrates to train Random Forest and Artificial Neural Network classifiers. XenoBug operates through three distinct modules: Module-1 employs two multilabel classifiers for reaction class prediction, Module-2 uses six multilabel models for reaction subclass prediction, and Module-3 utilises structural similarity searches for complete reaction prediction. This tool helps identify bacterial enzymes for pollutant breakdown , determine bacterial groups and pathways linked to specific pollutant degradation, helping in developing effective bioremediation approaches. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like The Most Remarkable Oscar Outfits Ever Interesticle Undo It enhances knowledge of pollutant-bacterial interactions and their biodegradation research stands out for its extensive enzyme substrate database, coverage of environmental bacterial genomes and metagenomes, and proven effectiveness across various pollutant types, including pesticides, environmental contaminants, pharmaceutical products, and hydrocarbons. The predictive algorithms analyse chemical structures and connect them with possible degradative pathways, simplifying the discovery of new bioremediation system's database includes numerous environmental samples, providing reliable predictions for various pollutant types. It handles queries related to persistent organic pollutants, pharmaceutical compounds, industrial chemicals, and agricultural pesticides. The machine learning models, trained using verified enzyme-substrate interactions, deliver reliable predictions. XenoBug's modular design enables systematic analysis of degradation pathways. "The practical benefits include faster identification of suitable bacterial strains for bioremediation projects, reduced laboratory testing costs, and more targeted experimental designs," said Prof Sharma. Environmental scientists can use these predictions to develop more effective clean-up strategies for contaminated areas, he added. This computational approach provides insights that are typically challenging to obtain through conventional laboratory methods.
Yahoo
10-02-2025
- Business
- Yahoo
Isothermal Nucleic Acid Amplification Technology Market to Worth Over US$ 17.26 Billion By 2033
Isothermal nucleic acid amplification technology market advances through rapid diagnostics, innovative integration, and international collaborations, empowering decentralized healthcare with precise testing solutions that redefine infectious disease monitoring worldwide for efficiency. New Delhi, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The global isothermal nucleic acid amplification technology market was valued at US$ 6.06 billion in 2024 and is projected to reach US$ 17.26 billion by 2033 at a CAGR of 12.34% during the forecast period 2025–2033. The isothermal nucleic acid amplification technology (INAAT) market is experiencing an unprecedented boom, driven by the increasing demand for rapid and accurate molecular diagnostic solutions. This substantial growth is fueled by the rising prevalence of infectious diseases, technological advancements in INAAT methods, and the growing need for point-of-care testing solutions. The market's expansion is further evidenced by the increasing adoption of INAAT across various sectors, with hospitals and healthcare centers accounting for a significant market share of approximately 40% in 2024. Download Free Sample Copy @ The isothermal nucleic acid amplification technology market's rapid growth is also reflected in the increasing number of INAAT-based diagnostic tests being performed globally. In 2023 alone, over 100 million rapid tests were conducted using Abbott's ID NOW platform, a leading INAAT-based diagnostic system. This surge in test volumes underscores the growing acceptance and reliance on INAAT for rapid disease detection. Furthermore, the market has seen a proliferation of INAAT applications beyond traditional healthcare settings, with over 5,000 food processing facilities worldwide adopting INAAT-based testing systems in 2023 for rapid pathogen detection. This expansion into diverse sectors highlights the versatility and broad applicability of INAAT, contributing to its robust market growth and promising future prospects in the field of molecular diagnostics. Key Findings in Isothermal Nucleic Acid Amplification Technology Market Market Forecast (2033) US$ 17.26 billion CAGR 12.34% Largest Region (2024) North America (44%) By Product Reagents (63%) By Technology Loop-Mediated Isothermal Amplification (18%) By End Users Hospitals (42%) By Application Infectious Diseases Diagnosis (37%) Top Drivers Accelerated need for on-site rapid infection detection technology in healthcare Expanding global outbreaks prompt investment in portable diagnostic innovations worldwide Increasing global research collaborations drive breakthroughs in isothermal amplification systems Top Trends Dynamic integration of advanced multiplexing technologies within modern point-of-care devices Rapid digital connectivity enhancements boost portable assay performance in clinics Innovative miniaturized system designs foster seamless mobile diagnostic testing adoption Top Challenges Ongoing complex scientific reproducibility constraints significantly limit ultra-sensitive detection capabilities Interlaboratory technical variability hinders consistent performance of advanced amplification protocols Difficulty in establishing standardized procedures challenges reproducible isothermal assay outputs Funding Frenzy: Investors Bet Big on INAAT's Promising Future The isothermal nucleic acid amplification technology market is witnessing a significant influx of investments, reflecting the growing confidence in its potential to revolutionize molecular diagnostics. Despite a general decline in funding rounds across industries in 2024, with total rounds decreasing by over 28% compared to the previous year, the INAAT sector has managed to attract substantial investments. This trend is particularly noteworthy given the cautious investment environment, indicating the strong faith investors have in INAAT's future prospects. The sector has seen a focus on strategic investments in high-growth areas, mirroring trends observed in other innovative fields like artificial intelligence. While specific data on INAAT funding rounds is limited, the broader trends in venture capital suggest a landscape of fewer but larger deals. This pattern could imply that successful INAAT companies are securing substantial funding when they demonstrate strong potential and innovation. For instance, in the broader healthcare and biotech sector, there have been instances of significant funding rounds, with some companies raising hundreds of millions of dollars. The investment outlook for isothermal nucleic acid amplification technology market remains positive, with investors advised to strategically position themselves in sectors with high growth potential. Given the innovative nature of INAAT technologies and their alignment with emerging trends in digital health and personalized medicine, companies in this space are likely to continue attracting interest from venture capitalists looking to capitalize on cutting-edge developments in molecular diagnostics. Technological Titans: Four INAAT Methods Leading the Diagnostic Revolution The isothermal nucleic acid amplification technology market is dominated by four groundbreaking methods that are revolutionizing molecular diagnostics: Loop-Mediated Isothermal Amplification (LAMP), Nucleic Acid Sequence-Based Amplification (NASBA), Strand Displacement Amplification (SDA), and Recombinase Polymerase Amplification (RPA). LAMP, known for its simplicity and robustness, has seen widespread adoption with over 10,000 research publications utilizing this technique in the past five years. Its versatility has led to the development of over 500 LAMP-based diagnostic kits for various pathogens, including SARS-CoV-2, influenza, and tuberculosis. NASBA, primarily used for RNA amplification, has been incorporated into more than 200 commercial diagnostic assays, particularly for the detection of RNA viruses and gene expression analysis. Strand Displacement Amplification (SDA) has gained traction in automated diagnostic platforms, with over 50 million SDA-based tests performed annually for the detection of sexually transmitted infections and hospital-acquired pathogens. The technology's high sensitivity has enabled the detection of as few as 10 copies of target DNA in clinical samples, significantly improving early disease diagnosis in the isothermal nucleic acid amplification technology market. Recombinase Polymerase Amplification (RPA) has emerged as a game-changer in point-of-care diagnostics, with more than 1,000 portable RPA devices deployed in resource-limited settings for rapid disease detection. The technique's ability to operate at room temperature has led to its integration in over 300 field-deployable diagnostic kits, enabling on-site testing for various infectious diseases. These four INAAT methods are not only advancing the field of molecular diagnostics but are also paving the way for personalized medicine and rapid response to emerging health threats. Application Explosion: INAAT's Expanding Reach Across Multiple Sectors The applications of isothermal nucleic acid amplification technology market have expanded far beyond traditional healthcare settings, revolutionizing diverse sectors such as food safety, environmental monitoring, and biodefense. In the food industry, INAAT has become an indispensable tool for rapid pathogen detection, with over 5,000 food processing facilities worldwide adopting INAAT-based testing systems in 2023. This adoption has led to a 40% reduction in foodborne illness outbreaks linked to contaminated products in countries where INAAT testing is widely implemented. The technology's speed and sensitivity have enabled the detection of pathogens like E. coli and Salmonella in less than 30 minutes, compared to traditional culture methods that can take days, significantly improving food safety protocols and reducing product recalls. In environmental monitoring, isothermal nucleic acid amplification technology market has found applications in water quality testing, soil analysis, and air sampling. Over 10,000 water treatment plants globally now use INAAT-based systems for real-time monitoring of microbial contamination, enabling rapid response to potential health hazards. In agriculture, INAAT has been employed in more than 500 large-scale farming operations for early detection of crop pathogens, reducing crop losses by up to 30% through timely intervention. The biodefense sector has also embraced INAAT, with over 100 military and civilian biodefense laboratories incorporating the technology into their rapid threat detection protocols. These systems can identify bioterrorism agents within 60 minutes, significantly enhancing response capabilities in the event of a biological attack. The versatility of INAAT has led to its integration in more than 1,000 portable field kits used by first responders and environmental agencies for on-site testing in various scenarios, from natural disasters to industrial accidents. Market Maestros: Key Players Shaping the INAAT Landscape The isothermal nucleic acid amplification technology market is characterized by intense competition and rapid innovation, with several key players dominating the landscape through their cutting-edge product offerings. Abbott Laboratories stands out as a market leader, with its ID NOW platform performing over 100 million rapid tests in 2023 alone. The company's INAAT portfolio has expanded to include 15 different assays for various infectious diseases, capturing a 30% market share in the point-of-care molecular diagnostics segment. Hologic, Inc. has made significant strides with its Aptima assays, which have been used in more than 200 million tests globally for sexually transmitted infections and respiratory pathogens. The company's Panther Fusion system, capable of processing up to 1,000 samples per day, has been adopted by over 2,000 clinical laboratories worldwide. Other notable players include bioMérieux SA, whose NucliSENS EasyQ system has been installed in over 1,500 laboratories globally, and Meridian Bioscience, Inc., which has sold more than 5 million units of its LAMP-based diagnostic kits in the past year. Eiken Chemical Co., Ltd., the pioneer of Loop-mediated Isothermal Amplification (LAMP) technology, has licensed its LAMP patents to more than 50 companies, fueling the development of numerous INAAT-based diagnostic kits. The company's own LAMP products in the isothermal nucleic acid amplification technology market have been used in over 50 countries, with more than 10 million tests performed annually for diseases such as tuberculosis and malaria. These key players are continuously investing in research and development, with Abbott allocating $500 million to INAAT innovation in 2023, and Hologic filing over 100 INAAT-related patents in the same year. The competitive landscape is further intensified by emerging startups, with over 30 new companies entering the INAAT market in the past two years, each bringing novel approaches to isothermal amplification and detection methods. Customize this report to your needs: End-User Evolution: Diverse Sectors Embrace INAAT's Transformative Power The end-user landscape for isothermal nucleic acid amplification technology market has undergone a significant evolution, with diverse sectors embracing its transformative power. Hospitals remain the largest end-users, with over 10,000 healthcare facilities worldwide integrating INAAT-based systems into their diagnostic workflows. This adoption has led to a 50% reduction in time-to-diagnosis for critical infectious diseases, significantly improving patient outcomes. Reference laboratories have also become major adopters, with more than 5,000 facilities globally utilizing INAAT for high-throughput testing. These labs collectively process over 100 million INAAT-based tests annually, covering a wide range of applications from infectious disease diagnostics to genetic testing. Academic and research institutes have embraced INAAT for its versatility in molecular biology applications. Over 2,000 research papers utilizing INAAT were published in 2023 alone, spanning fields from oncology to microbiology. The technology has been integrated into more than 500 university teaching labs, training the next generation of molecular biologists. Beyond traditional healthcare settings, isothermal nucleic acid amplification technology market has found applications in diverse industries. In agriculture, over 1,000 large-scale farms now use INAAT for rapid detection of crop pathogens, while the food industry has implemented INAAT-based testing in more than 5,000 processing facilities for quality control. Environmental agencies have deployed over 2,000 portable INAAT devices for field testing of water and soil samples, enhancing their ability to monitor ecosystem health. This widespread adoption across various sectors underscores INAAT's versatility and its potential to revolutionize molecular testing in numerous applications beyond healthcare. Global Isothermal Nucleic Acid Amplification Technology Market Key Players: Abbott Alere Inc. Becton, Dickson & Company Biohelix Corporation Biomerieux Biotechnology Company Eiken Chemical Co. Ltd Grifols S.A. Hologic Gene-Probe Lucigen Corporation Meridian Biosciences, Inc. Nugen Optigene Limited QIAGEN Company Quidel Corporation Tecan Genomics Inc. Thermos Fisher Scientific, Inc. Ustar Biotechnologies Ltd. Other Prominent Players Key Segmentation: By Technology Nicking Enzyme Amplification Reaction (NEAR) Nucleic Acid Sequence-based Amplification (NASBA) HDA LAMP SDA SPIA TMA RCA RPA SMAP2 Others By Application Blood Screening Infectious Disease Diagnostics Cancer Others By End-use Hospitals Central and Reference Labs Others By Region North America Europe Asia Pacific Middle East & Africa South America Contact us about this report before purchase: About Astute Analytica Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in to access your portfolio
